# Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)

Study · id `cardio:ct-nct05772169` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05772169](<https://clinicaltrials.gov/study/NCT05772169>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05772169

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1113 participants.

## Technical summary

Registry record NCT05772169. Randomized; triple masking; primary purpose treatment. Start 2023-03-31 (actual); primary completion 2024-11-19 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1113 participants (enrolled count; ClinicalTrials.gov record NCT05772169, source copy `cardio:ctgov-nct05772169-2025-01-20`, retrieved 2026-10-26)
- Started: 2023-03-31 (actual) (ClinicalTrials.gov record NCT05772169, source copy `cardio:ctgov-nct05772169-2025-01-20`, retrieved 2026-10-26)
- Primary completion: 2024-11-19 (actual) (ClinicalTrials.gov record NCT05772169, source copy `cardio:ctgov-nct05772169-2025-01-20`, retrieved 2026-10-26)
- Completion: 2024-12-18 (actual) (ClinicalTrials.gov record NCT05772169, source copy `cardio:ctgov-nct05772169-2025-01-20`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05772169, source copy `cardio:ctgov-nct05772169-2025-01-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05772169-2025-01-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
- Condition: Hypercortisolism
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Mifepristone 300 MG \[Korlym\]
- Intervention (Drug): Placebo for mifepristone
- Lead sponsor: Corcept Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Corcept Therapeutics (`cardio:org-corcept-therapeutics`)

## Provenance

Content hash: a2db7d54feec9289af5ec03bc5d57d6c0b87187847f2dd73512b19891b7de6f4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
